Prevalence of cytopenia(s) and somatic variants in patients with DDX41 mutant germline predisposition syndrome. British Journal of Haematology. 2025; 206:1109-1120.
.Germline DDX41 mutations in myeloid neoplasms: the current clinical and molecular understanding. Current Opinion in Hematology. 2025; 32:67-76.
.2024; 144:4089.
. The Most Common Somatic DDX41 Mutation (p.R525H) Causes Loss of an Essential Function and Is Selected Against in Human iPSC and Leukemia Models. Blood.2024; 144:3183.
. Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41 MT Germline Predisposition Syndrome. Blood.2024; 144:440.
. Prevalence and Clinical Features of Non-Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome. Blood.Absence of PNH-clones in DDX41mutant-GPS aids in their distinction from acquired BM failure syndromes. Leukemia Research: clinical and laboratory studies. 2024; 145:107561.
.DDX41 haploinsufficiency causes inefficient hematopoiesis under stress and cooperates with p53 mutations to cause hematologic malignancy. Leukemia. 2024; 38:1787-1798.
.2023; 142:4618.
. Clinical and Molecular Spectrum of Somatic Mosaic States in DDX41 mutant Germline Predisposition Syndromes. Blood.2023; 142:4104.
. Genetic Complementation Studies Reveal That Many Disease-Associated DDX41 Variants Do Not Cause Loss of Protein Function. Blood.Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms. Haematologica: the hematology journal. 2023; 108:3033-3043.
.Germline DDX41 mutant predisposition syndromes: Slow driver states to hematological malignancies. American Journal of Hematology. 2023; 98:1673-1676.
.2023; 4:a46.
. Abstract A46: Heterozygous mutations in DDX41 cause erythroid progenitor cell defects and cooperate with p53 mutations to cause hematologic malignancy. Blood Cancer Discovery.2023; 124:s70.
. 3040 – HETEROZYGOUS MUTATIONS IN DDX41 CAUSE ERYTHROID PROGENITOR CELL DEFECTS AND COOPERATE WITH P53 MUTATIONS TO CAUSE HEMATOLOGIC MALIGNANCY. Experimental Hematology.Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms. Current Hematologic Malignancy Reports. 2022; 17:113-120.
.The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia. Leukemia. 2022; 36:438-451.
.Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia. Cell Stem Cell. 2021; 28:1966-1981.e6.
.Inherited DNA Repair Defects Disrupt the Structure and Function of Human Skin. Cell Stem Cell. 2021; 28:424-435.e6.
.